EyePoint (EYPT) Interest & Investment Income (2010 - 2026)
EyePoint (EYPT) reported Interest & Investment Income of -$159000.0 for Q1 2026, down 51.43% on a YoY basis from -$327352.9 in Q1 2025, and down 478.57% sequentially from $42000.0 in Q4 2025.
EyePoint (EYPT) Interest & Investment Income (2010 - 2026) Analysis & Trends
EyePoint (EYPT) has 13 years of Interest & Investment Income data on file, last reported at -$159000.0 in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income fell 51.43% year-over-year to -$159000.0; the trailing twelve-month figure through Mar 2026 stood at -$121000.0 (down 239.08% YoY), and the FY2025 full-year result was -$67000.0, down 140.85% from the prior year.
- Interest & Investment Income retreated to -$159000.0 in Q1 2026, from $42000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $379000.0 in Q3 2024 to a low of -$186000.0 in Q2 2022.
- A 5-year average of -$2294.1 and a median of -$1000.0 in 2023 frame the typical range for Interest & Investment Income.
- Peak annual rise in Interest & Investment Income reached 38000.0% in 2024, while the deepest fall reached 4300.0% in 2024.
- Tracing EYPT's Interest & Investment Income over 5 years: stood at $133000.0 in 2022, then slumped by 82.71% to $23000.0 in 2023, then slumped by 721.74% to -$143000.0 in 2024, then soared by 129.37% to $42000.0 in 2025, then plunged by 478.57% to -$159000.0 in 2026.
- Business Quant data shows EYPT's Interest & Investment Income at -$159000.0 in Q1 2026, $42000.0 in Q4 2025, and $87000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | EyePoint | 1.07 Mn | -221.48 Mn | 168,000.00 | -159,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -159,000.00 |
| Dec 31, 2025 | 42,000.00 |
| Sep 30, 2025 | 87,000.00 |
| Jun 30, 2025 | -91,000.00 |
| Mar 31, 2025 | -105,000.00 |
| Dec 31, 2024 | -143,000.00 |
| Sep 30, 2024 | 379,000.00 |
| Jun 30, 2024 | -44,000.00 |
| Mar 31, 2024 | -28,000.00 |
| Dec 31, 2023 | 23,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Jun 30, 2023 | -1,000.00 |
| Mar 31, 2023 | 57,000.00 |
| Dec 31, 2022 | 133,000.00 |
| Sep 30, 2022 | 51,000.00 |
| Jun 30, 2022 | -186,000.00 |
| Mar 31, 2022 | -53,000.00 |
| Mar 31, 2017 | 1,000.00 |
| Sep 30, 2016 | 1,000.00 |
| Jun 30, 2015 | -16,000.00 |